Mar 21, 2019 8:00 am EDT Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
Feb 06, 2019 7:00 am EST Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Jan 24, 2019 7:00 am EST Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
Jan 22, 2019 7:00 am EST Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
Nov 13, 2018 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 12, 2018 7:00 am EST Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Nov 08, 2018 7:00 am EST Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
Nov 06, 2018 7:00 am EST Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
Nov 02, 2018 7:00 am EDT Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6